Testosterone Decline After 30: What's Genetic and What You Can Actually Change

Total testosterone on a standard blood panel is one of the most frequently ordered and least informative markers in men's health. The reference range — typically 300 to 1000 ng/dL depending on the lab — is wide enough to classify a man with significant symptoms and meaningfully impaired androgenic function as "normal." It tells you how much testosterone is circulating. It tells you nothing about how much is bioavailable, how sensitive your receptors are to it, how quickly it's being converted to oestradiol, or how well your cortisol axis is protecting it.

Each of these variables is substantially influenced by your genetics — which means two men with identical total testosterone readings can have dramatically different functional androgen status.

Why total testosterone is the wrong metric

Of the testosterone in circulation, approximately 44% is tightly bound to SHBG (sex hormone-binding globulin) and biologically inactive. Another 54% is loosely bound to albumin and partially bioavailable. Only 2-3% is free testosterone — the fraction that enters cells and activates androgen receptors. If your SHBG is high, a large proportion of your total testosterone is locked away and functionally irrelevant.

SHBG increases with age, which is one structural reason free testosterone declines faster than total testosterone as men age. But SHBG also has a substantial genetic component — the rs6257 and rs6259 variants in the SHBG gene account for meaningful population variation in SHBG expression. A man with genetically high SHBG can have total testosterone at the top of the reference range while his free testosterone is functionally low. The standard panel misses this entirely.

The aromatase conversion problem

CYP19A1 encodes aromatase, the enzyme converting testosterone into oestradiol. Some aromatisation is physiologically necessary — oestradiol plays important roles in male bone density, cardiovascular health, and libido. The problem is when activity is elevated, diverting a disproportionate fraction of testosterone into oestradiol.

CYP19A1 variants associated with higher enzyme expression — particularly those more active in adipose tissue — create a situation where testosterone production may be adequate but effective androgen levels are low because conversion is running fast. This is also why visceral adiposity compounds the problem: fat tissue is an aromatase site, so higher body fat drives higher conversion independently of genetics, though genetics set the baseline.

Men with elevated aromatase activity often present with symptoms indistinguishable from low testosterone — fatigue, reduced libido, mood changes, difficulty with body composition — but total testosterone is "normal." Without measuring oestradiol alongside testosterone, and without understanding the genetic context, the mechanism is invisible on standard bloodwork.

Zinc inhibits aromatase at the enzymatic level. DIM modulates oestrogen metabolism downstream. Resistance training consistently reduces aromatase activity in adipose tissue independently of weight loss. For men with genetically high aromatase, these are the mechanistically correct interventions — not testosterone supplementation, which increases substrate for an already-overactive conversion enzyme.

Androgen receptor sensitivity: the variable nobody measures

The androgen receptor (AR) CAG repeat polymorphism determines receptor transcriptional activity. Shorter CAG repeats confer higher sensitivity — more robust cellular response per unit of free testosterone. Longer repeats mean the receptor responds less efficiently to the same concentration.

Men with longer CAG repeats require higher free testosterone to achieve equivalent androgenic effects at the tissue level. When free testosterone is already reduced by SHBG elevation or aromatase conversion, the functional deficit compounds. A man with long CAG repeats and genetically high SHBG can be genuinely androgen-deficient at a total testosterone level that would be more than adequate for a man with short repeats and normal SHBG. The AR CAG repeat is invisible to any standard blood test — it is only measurable from your DNA.

The cortisol-testosterone competition

The HPA (stress) and HPG (sex hormone) axes compete for the same precursor: pregnenolone. Under chronic HPA activation, the body preferentially directs pregnenolone toward cortisol at the expense of testosterone synthesis. The NR3C1 glucocorticoid receptor gene — variants associated with heightened sensitivity mean the cortisol response is physiologically amplified and the pregnenolone competition is more pronounced. Men with high glucocorticoid receptor sensitivity under sustained stress will experience more significant testosterone suppression than men with lower sensitivity under equivalent conditions.

Ashwagandha (KSM-66 extract, 600mg daily) has the strongest evidence among adaptogens for cortisol reduction and consequent testosterone preservation in stressed men — with several randomised controlled trials showing significant effects on both. For men whose testosterone suppression is primarily stress-mediated, addressing the cortisol axis is the prerequisite, not testosterone optimisation.

What the evidence actually supports

Resistance training consistently produces 15-25% increases in testosterone in previously sedentary men. Sleep optimisation matters substantially — 70% of daily testosterone release occurs during sleep, and poor sleep quality reliably suppresses testosterone independent of other variables. Visceral fat reduction decreases aromatase activity and often increases free testosterone significantly without supplementation.

In supplementation, zinc and vitamin D have support specifically in deficient men — supplementing when replete shows minimal effect. Ashwagandha has consistent support for the cortisol-testosterone pathway. Beyond these, most testosterone-marketed supplements have weak or absent evidence.

The question your genetics can answer is which mechanism is actually driving your functional androgen status — SHBG elevation, aromatase conversion, receptor sensitivity, or cortisol competition. The answer determines the intervention. Without identifying the bottleneck, you're optimising blindly.

Want this applied to your actual variant profile?

Hormone DNA Report · $79 →